Axsome Therapeutics (AXSM) Invested Capital (2022 - 2025)
Historic Invested Capital for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $193.7 million.
- Axsome Therapeutics' Invested Capital fell 2901.12% to $193.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $193.7 million, marking a year-over-year decrease of 2901.12%. This contributed to the annual value of $237.0 million for FY2024, which is 3611.06% down from last year.
- Latest data reveals that Axsome Therapeutics reported Invested Capital of $193.7 million as of Q3 2025, which was down 2901.12% from $193.1 million recorded in Q2 2025.
- Axsome Therapeutics' 5-year Invested Capital high stood at $458.8 million for Q2 2023, and its period low was $64.7 million during Q1 2022.
- Moreover, its 4-year median value for Invested Capital was $252.4 million (2022), whereas its average is $260.6 million.
- As far as peak fluctuations go, Axsome Therapeutics' Invested Capital skyrocketed by 31633.96% in 2023, and later crashed by 3928.96% in 2024.
- Quarter analysis of 4 years shows Axsome Therapeutics' Invested Capital stood at $204.6 million in 2022, then skyrocketed by 81.36% to $371.0 million in 2023, then crashed by 36.11% to $237.0 million in 2024, then dropped by 18.26% to $193.7 million in 2025.
- Its Invested Capital was $193.7 million in Q3 2025, compared to $193.1 million in Q2 2025 and $233.2 million in Q1 2025.